Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: February 29, 2016
Event: Announcement of funding secured by the Company.
Key Financial Metrics
Funding Amount: $5.75 million
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics. This report focuses solely on the funding announcement.
Material Changes
The primary material change reported is the securing of $5.75 million in funding as of February 29, 2016. No comparative financial data or prior period metrics are included in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the funding but does not include specific management commentary, forward-looking guidance, or risk factors within the body of the 8-K text provided.
Unusual Items: None reported beyond the funding event.
Investor Verification Checklist
- Verify the terms and conditions of the $5.75 million funding (e.g., equity vs. debt, interest rates, maturity).
- Review the full text of the press release (Exhibit 99.1) for details on the use of proceeds.
- Confirm the impact of this funding on the Company's current liquidity position and capitalization structure.